COTA Partners with LCP Health Analytics to Enhance HTA Decision Making
US and UK Data to Address Key Evidence Gaps in Access to Medicines
LCP Health Analytics is collaborating with COTA to harness the power of US real-world data (RWD) to support health technology assessments (HTA) across international markets. As there are ongoing discussions about patient accessibility to innovative therapies in different regions, this partnership aims to utilize deidentified data from US multiple myeloma patients to influence reimbursement decisions in the UK.
This collaboration mixes COTA’s extensive oncology dataset with LCP's analytical expertise, paving the way for research that aims to identify US patient demographics that mirror those treated under National Health Service (NHS) protocols in the UK. For the first time, this initiative enables a direct comparison of real-world haematological oncology data between the US and the UK, which may help overcome existing barriers in sharing and utilizing cross-country data.
Once these comparable patient groups are established, the project will evaluate how suitable they are for consideration in HTAs within the UK and EU. The assessment criteria will include:
- Characterization of patient groups using clinical and demographic information
- Analysis of treatment practices and key outcomes such as survival rates, which are of interest to payers and HTA organizations
- Evaluation on the potential utility of these groups in future real-world studies that emulate clinical trial populations
This partnership follows LCP Health Analytics’ expansion with the recent introduction of their US Access Solutions service. Dr. Ben Bray, a partner and Evidence Generation Lead at LCP, expressed enthusiasm for this new partnership and the valuable insights anticipated from the collaboration. He noted that by combining healthcare data and expert knowledge from both the UK and US, important evidence can be generated to support HTA submissions and expedite patient access to novel treatments. Bray emphasizes the importance of such collaborative efforts in the future.
COTA is renowned for its extensive, high-quality oncology real-world data sourced from electronic health records across a mix of academic institutions and community care settings in the US. By employing advanced artificial intelligence tools for data abstraction and curation, COTA enables faster and more efficient analyses of real-world data to generate actionable insights for stakeholders in healthcare.
The traditional dependency of UK healthcare on US clinical trial data for HTA and regulatory evaluations is a challenge the partnership aims to address. By integrating diverse US RWD, insights into identifying applicable treatment groups relevant to the UK context may be achieved, facilitating faster delivery of treatments to eligible patients.
As noted by Dr. Andrew Thompson, a Senior Epidemiologist at LCP Health Analytics, the vast amounts of healthcare data generated in the US present unique opportunities for enriching the UK health context. Understanding how to effectively utilize this data is pivotal to generating robust evidence and fostering regulatory innovation that ultimately benefits patients.
CK Wang, MD, Chief Medical Officer of COTA, highlighted the transformative effects of real-world data and artificial intelligence in cancer treatment, acknowledging that while these tools expand possibilities, regulatory complexities can still introduce hurdles. Wang indicated that this collaboration stands to empower regulatory bodies and life sciences firms to utilize more comprehensive and refined data sets that expedite treatment on a global level.
About LCP
LCP is recognized for its expertise across various sectors including pensions, financial services, energy, health and sports analytics. The multidisciplinary team possesses a wealth of knowledge that empowers organizations to tackle complex challenges and seize opportunities within the market.
Driving solutions through a fusion of human insight and analytical skill, LCP helps clients navigate through uncertainties with informed decision-making that creates value not only for their businesses but also for society at large. Their commitment to problem-solving reflects a focus on building a positive future.
About COTA, Inc.
COTA, founded by a dedicated group of oncologists, is focused on revolutionizing cancer care through a patient-centric lens leveraging real-world data. The advanced technology-enabled methods of data abstraction allow for clarity within the vast array of complex patient data, ensuring high-quality oncology insights from both academic and community practices. COTA collaborates with leading life sciences companies and healthcare providers to ensure that every individual affected by cancer can find an accessible route to the most appropriate care.
Frequently Asked Questions
What is the primary goal of the COTA and LCP partnership?
The partnership aims to use US real-world data to support health technology assessments in the UK and Europe, enhancing access to oncology treatments.
How does this partnership plan to analyze patient groups?
It will involve characterizing patient demographics, examining treatment patterns, and assessing outcomes relevant to payers and HTA bodies.
What resources will COTA provide for this initiative?
COTA will offer its comprehensive oncology real-world data, utilizing advanced analytics tools to streamline data processing and insights generation.
What are some challenges in the current UK healthcare system that this partnership addresses?
The partnership seeks to overcome barriers related to accessing US clinical trial data and enhance the integration of US real-world data into UK healthcare evaluations.
Why is leveraging US RWD significant for international health technology assessments?
US RWD provides a robust dataset that can help inform decision-making, potentially leading to faster patient access to innovative therapies in other markets.
